Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN)
- PMID: 20350215
- DOI: 10.3109/00313021003631379
Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN)
Abstract
Aims: Pancreatic cancer is an aggressive tumour following a multistep progression model through precursors called pancreatic intraepithelial neoplasia (PanIN). Identification of reliable prognostic markers would help in improving survival. The aim of this study was to investigate the role as well as the prognostic significance of different cell cycle and proliferation markers, namely p21, p27, p53 and Ki-67, in pancreatic carcinogenesis.
Methods: We analysed the expression of p21, p27, p53 and Ki-67, in 210 ductal pancreatic adenocarcinomas, 40 PanIN-3 cases and 40 normal controls combined in a tissue microarray. The results were correlated with clinicopathological and follow-up data.
Results: Our study revealed a differential p27, p21, p53, and Ki-67 expression between ductal adenocarcinoma, PanIN-3 and normal pancreas. p27 expression progressively decreased from normal pancreas to PanIN and to pancreatic cancer. Decreased p27 and increased p53 expression showed a significant association with the T stage. A Ki-67 >5% correlated with reduced survival.
Conclusions: In pancreatic cancer, loss of p27 and increased p53 expression is associated with a more aggressive phenotype. p27 may play an important role in pancreatic carcinogenesis. A Ki-67 >5% independently predicted poor outcome.
Similar articles
-
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray.Mod Pathol. 2003 Sep;16(9):902-12. doi: 10.1097/01.MP.0000086072.56290.FB. Mod Pathol. 2003. PMID: 13679454
-
Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia.Cancer Res. 2001 Dec 15;61(24):8830-7. Cancer Res. 2001. PMID: 11751405
-
Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma.Am J Surg Pathol. 2007 Aug;31(8):1191-5. doi: 10.1097/PAS.0b013e31806841e1. Am J Surg Pathol. 2007. PMID: 17667542
-
Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.Semin Radiat Oncol. 2005 Oct;15(4):254-64. doi: 10.1016/j.semradonc.2005.04.001. Semin Radiat Oncol. 2005. PMID: 16183479 Review.
-
[Precursors to pancreatic cancer].Tidsskr Nor Laegeforen. 2006 Mar 23;126(7):905-8. Tidsskr Nor Laegeforen. 2006. PMID: 16554881 Review. Norwegian.
Cited by
-
Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma.Am J Cancer Res. 2018 Dec 1;8(12):2548-2563. eCollection 2018. Am J Cancer Res. 2018. PMID: 30662811 Free PMC article.
-
Phenethyl isothiocyanate inhibits proliferation and induces apoptosis in pancreatic cancer cells in vitro and in a MIAPaca2 xenograft animal model.Nutr Cancer. 2014;66(4):747-55. doi: 10.1080/01635581.2013.795979. Epub 2013 Nov 6. Nutr Cancer. 2014. PMID: 24195616 Free PMC article.
-
Combined utility of Ki-67 index and tumor grade to stratify patients with pancreatic ductal adenocarcinoma who underwent upfront surgery.BMC Surg. 2023 Dec 8;23(1):370. doi: 10.1186/s12893-023-02256-4. BMC Surg. 2023. PMID: 38066512 Free PMC article.
-
Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer.Br J Cancer. 2012 Aug 7;107(4):632-8. doi: 10.1038/bjc.2012.310. Epub 2012 Jul 17. Br J Cancer. 2012. PMID: 22805328 Free PMC article.
-
Proteomic and genomic profiling of pancreatic cancer.Cell Biol Toxicol. 2019 Aug;35(4):333-343. doi: 10.1007/s10565-019-09465-9. Epub 2019 Feb 15. Cell Biol Toxicol. 2019. PMID: 30771135 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous